|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.090 USD | +1.95% |
|
+5.03% | +16.11% |
| 05-13 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 05-13 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Protein and Genome Sequence Products | ||||||||||
Biotechnology (Startups) | 38.35M | 47.64M | 65.49M | 53.4M | 52.74M | |||||
Total Assets | 73.66M | 55.79M | 84.43M | 73.42M | 82.35M | |||||
Interest Expense | -6.29M | -2.53M | -3.18M | -1.06M | -1.19M | |||||
Income Tax Expense | - | 530K | 254K | 1.22M | 996K | |||||
CAPEX | -1.46M | -628K | -1.15M | -1.28M | -1.64M | |||||
EBT | -27.58M | -14.4M | 8.57M | 4.15M | -5.61M | |||||
Gross Profit | - | - | - | - | - | |||||
D&A | 1.12M | 1.09M | 1.19M | 1.3M | 1.46M | |||||
Operating Income | -20.46M | -13.01M | 10.46M | 3.92M | -5.5M | |||||
Net Income | -27.58M | -14.93M | 8.31M | 2.93M | -6.6M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Israel | - | - | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
- Stock Market
- Stocks
- PLX Stock
- Financials Protalix BioTherapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
